CoGenesys Phase 1 2a study is a randomized.

In the second phase, patients are to receive their chemotherapy prior to dosing, and a positive control group will receive Neulasta , a pegylated form of G-CSF. Ratings include safety and tolerability, pharmacokinetic profiles, and in addition in the second phase, signals to the effect. Martha A. Reitman, CoGenesys ‘ Senior Vice President, Medical Affairs, said: ‘The Phase 1 – 2a study builds on previous preclinical research shows that our long-acting form of G-CSF is likely a therapeutic profile similar to that of Neulasta , the current market leader for the treatment of patients with neutropenia.

).n cancer patients. Clinical programs with the beginning of Phase 1-2a Trial Of Neugranin in cancer patientsCoGenesys, announced today that it has Phase Phase 1 – 2a study in Europe Neugranin , a long-acting form of granulocyte colony stimulating factor . Neugranin is formed so as to reduce infection with neutropenia, a decrease in the number of white blood cells, which is associated with the most common adverse reaction associated with the administration of chemotherapy in cancer patients..idofact is committed the general standard of accessibility to drinking water power all public places, including bus and railway stations, To enhance galleries and conference centers.

Other entries from category "physiotherapy":

Random entries